Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Phase 1b trial of oral GLP-1 agonist HDM1002 shows weight reduction in Chinese adults with overweight/obesity
Can a new pill help with weight loss? Early trial shows promise
A phase 1b randomized controlled trial in Chinese adults with overweight/obesity without diabetes found greater weight reductions with oral …
A new oral weight-loss pill helped adults lose about 6 kilograms in just 28 days, showing early promise compared to a placebo.
GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
Could diabetes drugs help protect lungs? A new analysis of patient stories suggests a link
An analysis of 136 single-patient case reports from PubMed Open Access found that GLP-1 receptor agonist users had a lower risk of respirato…
Diabetes drugs linked to lower risk of serious lung problems in a new look at patient stories.
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
New-onset diabetes in adults over 50 associated with higher pancreatic cancer risk within 3 years
Could new diabetes after age 50 signal hidden pancreatic cancer?
A systematic review found individuals around 50 years and over with new-onset diabetes have a higher risk for pancreatic ductal adenocarcino…
New diabetes after age 50 might signal hidden pancreatic cancer, as patients face a higher risk of diagnosis within three years compared to …
Short-term liraglutide modulates proteins in obesity, showing weight-independent effects and myostatin suppression
Could a weight-loss drug work by changing your body's proteins?
A 5-week randomized trial in 20 adults with obesity found liraglutide 3 mg daily modulated 124 proteins, with 85% of effects persisting afte…
A weight-loss drug changed 124 blood proteins in a small study, with 85% of shifts not tied to weight loss, hinting at deeper body-wide effe…
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
Post hoc analysis links WHtR threshold to remission in obesity management with tirzepatide vs semaglutide
Could hitting specific weight targets help people feel better?
A post hoc analysis of the SURMOUNT-5 trial in participants with obesity found that 23.1%-33.9% on tirzepatide and 14.2%-20.7% on semaglutid…
People on tirzepatide who hit a waist-to-height ratio under 0.53 had more than double the odds of reaching remission compared to those who d…